Risedronate

ISSN： 1170-229X

Source： Drugs & Aging, Vol.13, Iss.1, 1998-07, pp. : 83-91

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

utrif Risedronate is a pyridinyl bisphosphonate that can be administered orally in lower dosages than other antiresorptive bisphosphonates. Like others of its class risedronate inhibits osteoclast-mediated bone resorption. utrif In experimental models of osteoporosis, risedronate inhibited bone loss and improved trabecular architecture. utrif In patients with Paget's disease, pain diminished or disappeared and serum alkaline phosphatase levels decreased after treatment with oral risedronate 30 mg/day for 3 months. utrif Risedronate 30 mg/day orally for 2 months significantly reduced pain, whereas etidronate 400 mg/day orally for 6 months tended to reduce pain, in a randomised double-blind trial of patients with Paget's disease. utrif Oral risedronate 5 mg/day for 2 years increased bone mass in postmenopausal women with low or normal bone mass. Risedronate 2.5 mg/day prevented bone loss in postmenopausal women treated with glucocorticoids for rheumatoid arthritis. utrif The incidence of gastrointestinal or other adverse events was similar in patients treated with risedronate or placebo in clinical trials.